RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Primary graft dysfunction is risk factor for a later serious lung transplant problem

Mar 1, 2007 - 5:00:00 AM
The researchers noted that additional studies are needed to further investigate the molecular mechanisms of primary graft dysfunction and its relationship to BOS.

 
[RxPG] Primary graft dysfunction, a common complication that affects up to 25 percent of lung transplant patients shortly after surgery, constitutes a significant risk factor for later deadly bronchiolotis obliterans syndrome (BOS).

This research appears in the first issue for March 2007 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Ramsey R. Hachem, M.D., of the Division of Pulmonary and Critical Care at Washington University School of Medicine in St. Louis, and eight associates examined the impact of primary graft dysfunction on the development of BOS in 320 lung transplant recipients.

BOS, a chronic scarring process that affects the small airways of the lungs years after transplant surgery, results in the progressive obliteration of the small airways with resulting obstructive lung disease. BOS is a leading cause of death after the one-year anniversary of a lung transplant.

We found that primary graft dysfunction is associated with an increased risk of BOS independent of certain other risk factors, including acute rejection and community-acquired respiratory viral infections, said Dr. Hachem.

Clinically and pathologically, primary graft dysfunction is a devastating form of acute lung injury that affects transplant patients in the first hours after they receive transplanted organs. The complication, which mimics adult respiratory distress syndrome, can be fatal for up to 50 percent of affected transplant patients.

Among the 320 recipients studied, 161 developed BOS, with the median time to onset at close to four years, said Dr. Hachem. Lung transplant recipients who did not have primary graft dysfunction had significantly greater freedom from BOS than those who developed any grade of primary graft dysfunction.

The researchers graded the severity of subjects' primary graft dysfunction according to the International Society for Heart and Lung Transplantation (ISHLT) definition. Those who did not have primary graft dysfunction immediately after transplantation were classified grade 0, while those with more severe graft dysfunction received a 1, 2 or 3.

In their analysis, the investigators found that all grades of primary graft dysfunction were associated with a significantly increased risk of BOS. Recipients with primary graft dysfunction grade 1 had the relative risk of 1.73; those with grade 2 had a relative risk of 2.13; and those with grade 3 were 2.53 times more likely to experience the later problem.

This association has important clinical implications and suggests that the immunosuppressive regimen should be optimized and that lung function should be monitored closely for patients who develop primary graft dysfunction, said Dr. Hachem.

The researchers noted that additional studies are needed to further investigate the molecular mechanisms of primary graft dysfunction and its relationship to BOS.

According to the ISHLT, this area of study is becoming increasingly important, as the number of lung transplants performed in the U.S. was a record 1,815 last year. They reported that survival was 78 percent at one year, 61 percent at three years, 49 percent at five years, and 25 percent at 10 years.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)